Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in sweden

Cancer Epidemiology

Volumn 38, Issue 4, 2014, Pages 442-447

  Banefelt, J ^a   Liede, A ^b   Mesterton, J ^a,c   Stalhammar J ^d   Hernandez, R K ^b   Sobocki, P ^c,e   Persson, B E ^f  

^a Quantify Research   (Sweden)

^b AMGEN INC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e IQVIA   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

ADT; CRPC; Metastasis; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; OUTPATIENT; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SWEDEN; UROLOGY; BLOOD; EPIDEMIOLOGY; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SWEDEN;

EID: 84904551263     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.04.007     Document Type: Article

References (23)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Socialstyrelsen (National Board of Health and Welfare) Cancer Incidence in Sweden 2010, 1. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18204/2010-12-17.pdf [accessed 21.08.11].
3. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.
4. Makarov D.V., Humphreys E.B., Mangold L.A., Carducci M.A., Partin A.W., Eisenberger M.A., et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008, 179(1):156-161. discussion 61-62.
5. Donovan M.J., Hamann S., Clayton M., Khan F.M., Sapir M., Bayer-Zubek V., et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008, 26(24):3923-3929.
6. Kawakami J., Cowan J.E., Elkin E.P., Latini D.M., DuChane J., Carroll P.R., et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006, 106(8):1708-1714.
7. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294(2):238-244.
8. Gilbert S.M., Kuo Y.F., Shahinian V.B. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol 2009, 29(6):647-653.
9. Shahinian V.B., Kuo Y.F., Gilbert S.M. Reimbursement policy and androgen-deprivation therapy for prostate cancer. New Engl J Med 2010, 363(19):1822-1832.
10. Shulman M.J., Benaim E.A. The natural history of androgen independent prostate cancer. J Urol 2004, 172(1):141-145.
11. Abouassaly R., Paciorek A., Ryan C.J., Carroll P.R., Klein E.A. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 2009, 115(19):4470-4476.
12. Smith M.R., Saad F., Coleman R., Shore N., Fizazi K., Tombal B., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379(9810):39-46.
13. Smith M.R., Kabbinavar F., Saad F., Hussain A., Gittelman M.C., Bilhartz D.L., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005, 23(13):2918-2925.
14. Smith M.R., Saad F., Oudard S., Shore N., Fizazi K., Sieber P., et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013, 31(30):3800-3806.
15. Martinell M., Stalhammar J., Hallqvist J. Automated data extraction - a feasible way to construct patient registers of primary care utilization. Ups J Med Sci 2012, 117:52-56.
16. Barlow L., Westergren K., Holmberg L., Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009, 48(1):27-33.
17. Ludvigsson J.F., Andersson E., Ekbom A., Feychting M., Kim J.-L., Reuterwall C., et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011, 11(450).
18. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40(5):373-383.
19. Quan H., Sundararajan V., Halfon P., Fong A., Burnand B., Luthi J.-C., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43(11):1130-1139.
20. MSKCC. Available from: [cited 17.12.12]. http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx.
21. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
22. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94(446).
23. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008, 167(4):492-499.